Welcome to our dedicated page for Ocugen SEC filings (Ticker: OCGN), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Ocugen, Inc. (NASDAQ: OCGN) SEC filings page on Stock Titan provides direct access to the company’s regulatory disclosures as filed with the U.S. Securities and Exchange Commission. These documents are central for understanding Ocugen’s development plans in gene therapies for blindness diseases, its financial condition, and key corporate actions.
Ocugen uses Form 8‑K current reports to announce material events, including exclusive licensing agreements, registered direct offerings of common stock and warrants, litigation developments, and Nasdaq listing compliance updates. For example, recent 8‑K filings describe an exclusive license agreement with Kwangdong Pharmaceutical Co., Ltd. for OCU400 in the Republic of Korea, a securities purchase agreement for a registered direct offering, and court decisions related to a securities class action lawsuit.
Periodic reports such as Form 10‑Q and Form 10‑K (when available) provide more comprehensive information on Ocugen’s financial results, operating expenses, and risk factors. In a recent earnings-related press release furnished on Form 8‑K, the company detailed revenue from collaborative arrangements, research and development expenses, general and administrative expenses, and net loss figures, along with commentary on cash runway and financing plans.
Investors can also review filings that discuss executive compensation and equity awards, such as performance restricted stock units granted to senior leadership, and agreements related to licensing, supply, and regional commercialization of products like OCU400. These filings help clarify how management is incentivized and how Ocugen structures partnerships around its modifier gene therapy platform.
On Stock Titan, Ocugen’s SEC filings are updated in near real time from the EDGAR system. AI-powered tools summarize lengthy documents, highlight key sections on clinical programs, licensing terms, capital raises, and governance matters, and make it easier to locate items such as quarterly results, material agreements, and other disclosures relevant to OCGN stock.
Ocugen, Inc. appointed Rita Johnson-Greene as Chief Financial Officer effective February 9, 2026, with her role as principal financial officer beginning after the filing of the Annual Report for the year ended December 31, 2025. Current principal financial officer Ramesh Ramachandran will continue as Chief Accounting Officer and principal accounting officer.
Under her employment agreement, Ms. Johnson-Greene will receive a $440,000 annual base salary, an initial target bonus opportunity of up to 45% of base salary, and a $90,000 sign-on bonus subject to repayment if she departs within one year. She was granted options to purchase 750,000 shares of common stock and 500,000 restricted stock units that vest in equal annual installments over three years. The agreement includes 12 months of salary continuation and COBRA premium support upon certain terminations, with additional bonus and full equity vesting acceleration if such a termination occurs around a change in control.
The Vanguard Group filed a Schedule 13G reporting a passive ownership stake in Ocugen Inc. common stock. Vanguard reports beneficial ownership of 16,475,562 shares, representing 5.27% of the class as of 12/31/2025.
Vanguard has shared voting power over 1,981,345 shares and shared dispositive power over 16,475,562 shares, with no sole voting or dispositive power. The filing states the securities are held in the ordinary course of business and not for the purpose of influencing control of Ocugen.
Ocugen, Inc. completed its previously announced underwritten offering of 15,000,000 shares of common stock at $1.50 per share. The company states that the proceeds from this stock sale are expected to extend its cash runway into the fourth quarter of 2026, giving it more time to fund operations and development plans without needing additional financing in the near term. The transaction and related details were also highlighted in a press release filed as an exhibit.
Ocugen, Inc. entered into an underwriting agreement with Oppenheimer & Co. Inc. to sell 15,000,000 shares of common stock at $1.50 per share in an underwritten public offering. The offering is expected to close on or about January 22, 2026, subject to customary closing conditions.
Ocugen expects to receive approximately $20.8 million in net proceeds after underwriting discounts, commissions and estimated expenses. The company plans to use the cash for general corporate purposes, capital expenditures, working capital, and general and administrative expenses. The shares are being issued under an effective Form S-3 shelf registration and a January 20, 2026 prospectus supplement.
Ocugen, Inc. is offering 15,000,000 shares of common stock at $1.50 per share, for gross proceeds of $22.5 million and estimated net proceeds of about $20.85 million. The company expects to use the cash for general corporate purposes, including working capital, capital expenditures, and administrative costs, and may also invest in complementary businesses or technologies.
Shares outstanding will rise from 312,319,623 as of September 30, 2025 to 327,888,374, creating immediate dilution of $1.43 per share for new investors based on an as adjusted net tangible book value of $0.07. Ocugen highlights ongoing losses, substantial doubt about its ability to continue as a going concern without additional funding, and the likelihood of further capital raises. The filing also describes late-stage gene therapy programs, including OCU410 and OCU400, with recent positive clinical data in retinal diseases.
Ocugen, Inc. filed a report describing new clinical progress for its eye disease pipeline. The company announced positive preliminary 12‑month data from both its Phase 1 and Phase 2 ArMaDa trials of OCU410 (AAV5‑RORA), a modifier gene therapy candidate being studied for geographic atrophy caused by dry age‑related macular degeneration, a severe form of vision loss.
Ocugen also furnished a press release and an investor presentation as exhibits, which elaborate on the OCU410 results and program. The company cautions that these findings are preliminary and that clinical trial data, including from OCU400 and OCU410ST, may differ as studies progress and as regulators review results. It highlights the possibility that new or reanalyzed data could be interpreted differently and refers readers to its prior annual and other reports for a fuller discussion of risks.
Ocugen, Inc. reported new equity awards to its Chief Executive Officer and director, Shankar Musunuri. On January 2, 2026, he received 3,123,201 performance stock units, each representing a contingent right to one share of common stock upon achievement of performance goals and continued service. On the same date, he was also granted an option to buy 3,123,201 shares of common stock at an exercise price of $1.38 per share, vesting annually in equal installments over three years starting January 2, 2027, subject to continued service.
Following these transactions, Musunuri beneficially owned 4,955,924 shares of Ocugen common stock directly and 1,145,299 shares indirectly through KVM Holdings, LLC, where he has voting and investment power over the shares held.
Ocugen, Inc. reported that its Board of Directors approved a special equity grant for its Chief Executive Officer, Dr. Shankar Musunuri. On December 12, 2025, following a review of his total equity ownership versus founder CEOs in the company’s peer group, the Board authorized an additional award of 9,369,604 Performance Restricted Stock Units (PSUs), to be granted on January 2, 2026, on top of his regular annual equity award.
The PSUs carry a three-year performance period ending December 31, 2028. Vesting depends on the Compensation Committee determining that specific milestones have been achieved: two-thirds of the PSUs are tied to certain regulatory milestones, and one-third depends on a stock performance-related milestone during the performance period. The units will be settled in common stock once the Compensation Committee certifies milestone achievement, and only if Dr. Musunuri continues serving with Ocugen through the applicable achievement date; any unearned or unvested PSUs at the end of the period, or upon termination, will be forfeited.
Ocugen, Inc. filed its Q3 2025 10-Q, reporting collaborative revenue of $1.75 million and a net loss of $20.05 million (basic/diluted loss per share $0.07). Operating expenses were $19.38 million, driven by R&D of $11.15 million and G&A of $8.23 million. Interest expense rose to $1.31 million in the quarter.
Cash was $32.57 million and total assets $57.60 million at September 30, 2025. Total liabilities were $54.06 million, leaving stockholders’ equity at $3.53 million. Management disclosed substantial doubt about the company’s ability to continue as a going concern within one year due to expected funding needs. Cash used in operations for the nine months was $43.00 million.
Financing included an August 2025 registered direct offering of 20,000,000 shares plus 20,000,000 warrants for $18.5 million net, and the November 2024 Avenue loan with $30.0 million principal outstanding. The NeoCart merger agreement with Carisma was terminated on September 16, 2025. Common shares outstanding were 312,320,112 as of October 31, 2025.
Ocugen (OCGN) reported financial results for the quarter ended September 30, 2025 and scheduled a conference call and webcast for 8:30 a.m. Eastern Time on November 5, 2025 to discuss results and business updates. The company posted related presentation materials on its website.
The press release and presentation were furnished as Exhibits 99.1 and 99.2 under Item 2.02, and are not deemed filed for liability purposes under Section 18 of the Exchange Act.